Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2024

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062

Cai L,

Jiang C,

Zhang G,

Fang H,

Wang J,

Li Y,

Xu H,

Xiao R,

Ding Y,

Huang K,

Zhang C,

Zhang L,

Chen B,

Duan X,

Pan W,

Han G,

Chen R,

Liu L,

Zhang S,

Tao J,

Pang X,

Yu J,

Wang H,

Zhao Y,

Li C,

Kang X,

Qin L,

Zhu X,

Su J,

Li S,

Yang C,

Feng W,

Lei T,

Jiang S,

Fang R,

Lin M,

Lu Q,

Xu C,

Wang W,

Zhang J

Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.

Keywords:

July 2024

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

Journal Reference: Arthritis Res Ther 2024;26:143 doi: 10.1186/s13075-024-03358-x

Khan N,

Bu X,

Li Y,

Penn SK,

Camp HS,

Aelion J

van Vollenhoven et al. compared the efficacy and safety of upadacitinib monotherapy to methotrexate monotherapy over five years in methotrexate-naïve patients with rheumatoid arthritis. The study found that upadacitinib provided better long-term efficacy and higher rates of disease activity remission than methotrexate; however, it was associated with higher incidences of adverse events, particularly at the higher dose of 30 mg.

Keywords:

May 2024

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the Phase 3, randomised SELECT-COMPARE study

RMD Open 2024;10:e004007 doi: 10.1136/rmdopen-2023-004007

Fleischmann R,

Swierkot J,

Penn SK,

Durez P,

Bessette L,

Bu X,

Khan N,

Li Y,

Peterfy CG,

Tanaka Y,

Mysler E

More RA patients on upadacitinib versus adalimumab achieved clinical remission, LDA, and DAS28 (CRP) <2.6. Radiographic progression was less with continuous upadacitinib versus continuous adalimumab. Upadacitinib showed similar safety to adalimumab, with higher incidences of HZ, lymphopenia, CPK elevation, hepatic disorder and nonmelanoma skin cancer.

Keywords:

Upadacitinib in active non-radiographic axial spondyloarthritis: 1-year data from a double-blind, randomized, placebo-controlled, Phase 3 trial

ACR Open Rheumatol 2024 doi: 10.1002/acr2.11669 Epub ahead of print

Kim TH,

Li Y,

Wung P,

The 1-year results of the SELECT-AXIS 2 study showed significant improvements in ASAS40 achievement in patients with nr-axSpA that were treated with upadacitinib 15mg QD versus placebo. Improvements in ASDAS endpoints, back pain, BASFI, and hsCRP from baseline were also observed.

Keywords:

September 2023

Efficacité et sécurité de l'Upadacitinib chez les patients atteints de spondylarthrite ankylosante réfractaire aux traitements biologiques : résultats à un an de l'extension ouverte d'une étude de phase III

Arthritis Res Ther 2023; 2023;18;25(1):172 doi 10.1186/s13075-023-03128-1

Inman R,

Li Y,

Bu X,

Shmagel A,

Wung P,

Song I,

Deodhar A

The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.

Keywords:

July 2023

Upadacitinib chez les patients atteints de rhumatisme psoriasique et avec une réponse inadéquate aux médicaments biologiques : résultats à 3 ans de l'extension ouverte de l'étude SELECT-PsA 2 de phase 3 randomisée et contrôlée

Clin Exp Rheumatol. 2023;41(11):2286–2297 doi: 10.55563/clinexprheumatol/8l7bbk.

Mease P,

Setty A,

Papp K,

Tsuji S,

Li Y,

McDearmon-Blondell E,

Wung P,

Tillett W

Data from this open-label extension showed the efficacy of upadacitinib observed at 56 weeks was maintained through to 152 weeks in the treatment of patients with PsA. No cumulative adverse effects were observed, and no new safety signals were identified.

Keywords:

August 2022

Upadacitinib pour le traitement de la spondylarthrite axiale active non radiographique (SELECT-AXIS 2) : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo

Lancet 2022 doi: 10.1016/S0140-6736(22)01212-0

Kim TH,

Duan Y,

Li Y,

Pangan AL,

Wung P,

Song IH

Upadacitinib significantly improved the signs and symptoms of nr-axSpA compared with placebo at Week 14 in this investigation. Prior to this, upadacitinib had been shown to be effective in patients with AS. This study aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.

Keywords:

April 2022

Évaluation de la réponse à la vaccination anti-pneumococcique conjuguée 13-valent chez les patients atteints de polyarthrite rhumatoïde recevant de l'upadacitinib : résultats d'une étude d'extension ouverte de phase 2

RMD Open. 2022;8(1):e002110 doi: 10.1136/rmdopen-2021-002110

Li Y,

Klaff J,

Kivitz A

Vaccine sub-study of the BALANCE-EXTEND upadacitinib trial finds that approximately two-thirds of patients receiving upadacitinib 15 mg once-daily achieve a satisfactory humoral response to pneumococcal 13-valent conjugate (PCV-13) vaccine, despite receiving concomitant methotrexate (MTX).It is well known that a weakened immune response, comorbidities and immunosuppressant drug therapy all contribute to an increased susceptibility to infections in patients with RA. Likewise, the morbidity and mo...

Keywords:

March 2022

Innocuité et efficacité à long terme de l'upadacitinib ou de l'adalimumab chez les patients atteints de polyarthrite rhumatoïde : résultats à 3 ans de l'étude SELECT-COMPARE

RMD Open. 2022;8(1):e002012 doi: 10.1136/rmdopen-2021-002012

Durez P,

Khan N,

Bu X,

Li Y,

Song IH

Upadacitinib continues to show consistently better clinical responses, compared with adalimumab, through 3 years, including rates of remission and low disease activity, physical function and pain severity.Following the favourable upadacitinib efficacy data seen in the SELECT-COMPARE study at 72 weeks, Fleischmann, et al. assessed the long-term safety and efficacy of upadacitinib versus adalimumab over 3 years in the long-term extension of this study, with promising results. ...

Keywords:

January 2022

Inhibition de la progression des lésions articulaires structurelles avec l'upadacitinib dans la polyarthrite rhumatoïde : résultats à un an du programme de phase 3 SELECT

Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861

Hall S,

Durez P,

Shaw T,

Li Y,

Chen S,

Song IH